Challenges in managing NSAID-associated gastrointestinal tract injury

Digestion

Volumn 69, Issue SUPPL. 1, 2004, Pages 25-33

  Goldstein, Jay L ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aspirin; COX 2 selective inhibitors; Gastroprotective agents; NSAIDs; Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; NAUSEA; PEPTIC ULCER BLEEDING; PRIMARY PREVENTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ULCER HEALING; VOMITING;

ABDOMINAL PAIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; HUMANS; NAUSEA; PEPTIC ULCER; RISK FACTORS; VOMITING;

EID: 1542313856     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076554     Document Type: Conference Paper

References (34)

1. Goldstein JL, Eisen GM, Burke TA, Pena BM, Lefkowith J, Geis GS: Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002;16:819-827.
2. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L: Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-39.
3. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG: Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-1337.
4. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-249.
5. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
6. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-1078.
7. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-1670.
8. Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: In incidence and risk factor models. Am J Med 1991;91:213-222.
9. Pietzsch M, Theuer S, Haase G, Plath F, Keyser M, Riethling AK: Results of systematic screening for serious gastrointestinal bleeding associated with NSAIDs in Rostock hospitals. Int J Clin Pharmacol Ther 2002;40:111-115.
10. Agrawal N: Risk factors for gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs). J Fam Pract 1991;32:619-624.
11. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
12. Hung J: Medical Issues Committee of the National Heart Foundation of Australia: Aspirin for cardiovascular disease prevention. Med J Aust 2003;179:147-152.
13. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF: Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-1536.
14. Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-532.
15. Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, Swanell AJ, Sturrock RD, Hawkey CJ: Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997;112:1817-1822.
16. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM: Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455-1461.
17. Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, Thorhallsson E, Unge P: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753-758.
18. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-726.
19. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-734.
20. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B: NSAID-Associated Gastric Ulcer Prevention Study Group: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002;162:169-175.
21. Chey WD, Lukasik N, Huang B, Joseph-Ridge N: Lansoprazole effectively reduces the risk of GI symptom occurrence in ulcer free patients who continue chronic NSAID use. Am J Gastroenterol 2003;98:S269.
22. Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, Hu HC, Wong WM, Chan OO, Chan CK: Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in non-steroidal anti-inflammatory drug users - a randomized trial. Aliment Pharmacol Ther 2003;18:829-836.
23. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.
24. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
25. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624-627.
26. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-1012.
27. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110.
28. Kelley DJ, Shah JP: Management of Barrett's oesophagus. Lancet 1996;348:561-562.
29. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
30. Goldstein JL, Joseph-Ridge N, MacDonald PA, Huang B, Collis CM, Chao CY, Ballard D: Lansoprazole provides gastroprotection in high-risk arthritis patients taking daily aspirin and chronic NSAIDs. Pharmacotherapy 2003;23:71E.
31. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-2038.
32. Sturkenboom MCJM, Burke TA, Dieleman JP, Lee F, Goldstein JL: Underutilization of gastroprotective strategies is common in patients at heightened risk for nonsteroidal antiinflammatory drug-associated upper gastrointestinal ulcer complications. Gut 2003;52(suppl VI):A16.
33. Sturkenboom MCJM, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL: Adherence to proton pump inhibitors and histamine-2 receptor antagonists used for the prevention of upper gastrointestinal (UGI) ulcer complications among non-specific NSAID users is suboptimal. Gut 2003;52(suppl VI):A94.
34. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M: Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-2200.